Search

Showing "11155" results for ""

High prevalence of cancerous and pre-cancerous cervical cell changes in HIV-positive women in Zambian study

Oral solution of tipranavir/ritonavir shows promise for treatment-experienced kids

Researchers launch hunt for people who control HIV without drugs

Anal cancer increases in French HIV cohort, despite use of antiretroviral therapy

Ranbaxy presents bioequivalence data on two paediatric fixed dose triple combination tablets

Abacavir/3TC backbone proves most durable for children over five years

Mixed results on ELISPOT TB testing in resource-limited settings

Single-dose nevirapine not jeopardising mother's treatment, large Zambian study reports

New data shed light on poor outcome in SMART study

Merck launches expanded access programme for integrase inhibitor

TNX-355, new entry inhibitor, effective in highly treatment-experienced patients

Maraviroc raises CD4 counts in patients with mixed-tropism virus, may offer value for highly treatment-experienced

Kaletra monotherapy as effective as triple therapy for at least 18 months

Efavirenz more durable than Kaletra over two years in treament-naive patients

Access to treatment associated with declining stigma in Botswana

Vicriviroc effective in treatment-experienced patients, but malignancy questions remain unanswered

The limits of PEP: saturation knowledge does not mean saturation use

MK-0518 integrase inhibitor effective in treatment-naive patients

Receive the latest HIV research and conference news

Showing "11155" results for ""

High prevalence of cancerous and pre-cancerous cervical cell changes in HIV-positive women in Zambian study

Oral solution of tipranavir/ritonavir shows promise for treatment-experienced kids

Researchers launch hunt for people who control HIV without drugs

Anal cancer increases in French HIV cohort, despite use of antiretroviral therapy

Ranbaxy presents bioequivalence data on two paediatric fixed dose triple combination tablets

Abacavir/3TC backbone proves most durable for children over five years

Mixed results on ELISPOT TB testing in resource-limited settings

Single-dose nevirapine not jeopardising mother's treatment, large Zambian study reports

New data shed light on poor outcome in SMART study

Merck launches expanded access programme for integrase inhibitor

TNX-355, new entry inhibitor, effective in highly treatment-experienced patients

Maraviroc raises CD4 counts in patients with mixed-tropism virus, may offer value for highly treatment-experienced

Kaletra monotherapy as effective as triple therapy for at least 18 months

Efavirenz more durable than Kaletra over two years in treament-naive patients

Access to treatment associated with declining stigma in Botswana

Vicriviroc effective in treatment-experienced patients, but malignancy questions remain unanswered

The limits of PEP: saturation knowledge does not mean saturation use

MK-0518 integrase inhibitor effective in treatment-naive patients

Receive the latest HIV research and conference news